Table 3. Probing of 14 microarray data sets of human cancer with the B-*myb* signature by using the Gene Set Enrichment Analysis method

Phenotype	Enrichment Score	Normalized Enrichment	PValue
Lung p53+ (Beer *et al*)	**0.3272**	**2.7593**	**0.007**
Lymph Node Metastatic Gastric (Chen *et al*)	0.2477	2.6738	0.007
Recurrent Hepatic Carcinoma (Yamaguchi *et al*)	0.2406	1.5807	0.073
Acute Lymphoblastic Leukemia (Golub *et al*)	0.2347	0.9742	0.158
Poor Outcome Medulloblastoma *et al*)	0.2076	0.7808	0.224
Metastatic Medulloblastoma *et al*)	0.2458	0.6022	0.271
Recurrent Prostate Cancer (Febbo *et al*)	0.1803	0.5889	0.286
Poor Outcome Lung Adenocarcinoma (Beer *et al*)	0.1898	0.3833	0.316
Good Outcome Lung Adenocarcinoma (Beer *et al*)	0.1862	0.249	0.325
Good Outcome Lymphoma (Monti *et al*)	0.1990	0.3555	0.344
Poor Outcome Glioma (Nutt *et al*)	0.1681	0.275	0.387
Anaplastic Oligodendroglioma (Nutt *et al*)	0.1827	0.1648	0.394
Metastatic Tumors *et al*)	0.1662	0.1557	0.394
Poor Outcome Lung Cancer (Banerjee *et al*)	0.1721	0.2549	0.419
Nonrecurrent Prostate Cancer Febbo *et al*)	0.1678	0.2348	0.442
Recurrent Breast Cancer (unpublished	0.1603	0.005	0.448
Good Outcome Lung Cancer (Banerjee *et al*)	0.1605	0.0502	0.485
Classic Glioblastoma (Nutt *et al*)	0.1605	0.3952	0.612
Good Outcome Glioblastoma (Nutt *et al*)	0.1321	0.5374	0.691
Poor Outcome Lymphoma (Monti *et al*)	0.1484	0.6732	0.743
Nonrecurrent Breast Cancer (unpublished	0.1361	0.7377	0.749
Lung p53- (Beer *et al*)	0.1473	0.7918	0.760
Nonmetastatic Medulloblastoma (McDonald *et al*)	0.1549	0.8469	0.799
Nonmetastatic Tumors (Ramawamy *et al*)	0.1284	0.9752	0.839
Primary Tumor Site Gastric Adenocarcinoma (Chen *et al*)	0.1158	1.3156	0.911
Nonrecurrent Hepatic Carcinoma *et al*)	0.1124	1.3768	0.928
Acute Myeloid Leukemia Golub *et al*)	0.1233	1.4455	0.958

A statistically significant association between the B-*myb* signature and p53 status was found in a set of 85 human lung adenocarcinomas.